Clinical Trials Logo

Clinical Trial Summary

When patients are dying they become unable to take oral medication and if they develop symptoms (e.g. pain or agitation) they need to be given a subcutaneous injection of medication. If they are at home this requires that a District Nurse is called and it can take a long time (sometimes hours) for the Nurse to arrive. This can be a very stressful time for the patient and family.

There are 2 drug preparations which could potentially be given by family members in the home:

Nasal fentanyl (PecFent) Buccal midazolam (Epistatus) If these preparations helped symptoms this would give much quicker symptom control for patients and might mean the District Nurse visit was not needed.

In advance of a community based randomised trial of these modes of administration, it is important to assess the feasibility of such an approach in terms of carer acceptability and patient tolerability as well as determine appropriate sample sizes and sampling methods. There are 2 work packages which would help assess feasibility of a community trial:

1. An open label randomised controlled trial comparing the use of PecFent with or without Epistatus versus standard subcutaneous breakthrough medication for the management of breakthrough pain (with or without agitation) in dying hospice patients who either remain in the hospice or go home.

2. A qualitative interview study to capture the thoughts of relatives of these patients about the use of these preparations.


Clinical Trial Description

This will be an open-label, randomized, controlled feasibility pilot study to evaluate whether using nasal fentanyl (PecFent: 100, 200, 400 or 800 mcg) alone or in combination with buccal midazolam (Epistatus: 2.5, 5 or 10 mg) has the possibility to give better breakthrough symptom control to dying patients when compared with standard subcutaneous medication (Figure 1 A and B).

Each subject and their carers/family members will receive verbal and written information followed by signing of the Informed Consent Forms (ICFs). The study is divided into two arms. In both arms patients will receive standard regular oral or subcutaneous medication for relieving non-breakthrough symptoms. In the standard care arm, patients will receive standard as needed medication (SANM) administered orally, sublingually or subcutaneously for breakthrough symptoms. The experimental arm will consist of two stages: in Stage 1 of the study, PecFent will be given to patients in order to treat breakthrough pain instead of subcutaneous opioids. PecFent will be titrated in order to establish an effective treatment dose to manage pain. SANM administered orally, sublingually or subcutaneously will be used to treat agitation and other symptoms.

After the effective treatment dose of PecFent has been established patients will enter stage 2. Patients will not move to stage 2 if the treatment dose of PecFent is not deemed effective. Stage 2 will test a range of doses of Epistatus in terms of efficacy in treating agitation alone instead of subcutaneous midazolam (or in combination with the effective treatment dose of PecFent for pain and agitation).

SANM will be used to treat other symptoms. Assessment of effectiveness of any as needed medication will be conducted at 30 minutes from administration. If PecFent, Epistatus or a combination of both is ineffective, administration of SANM will be considered. Further opioid cannot be given within one hour but benzodiazepine can be given within 30 minutes as is standard practice in this setting. Thus, patients in the experimental arm will receive symptom relief regardless the efficacy of test drugs. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02009306
Study type Interventional
Source Gloucestershire Hospitals NHS Foundation Trust
Contact
Status Completed
Phase Phase 4
Start date January 23, 2017
Completion date February 28, 2018

See also
  Status Clinical Trial Phase
Recruiting NCT05054907 - Using Wearable Device to Improve Quality of Palliative Care
Recruiting NCT05222308 - Advanced Planning for Online Accounts and Data N/A
Recruiting NCT06108375 - Differences in Acceptability of Music Therapy Sessions Played Live Compared to a Recording Thereof N/A
Active, not recruiting NCT04950608 - Pilot Study of Psilocybin-Assisted Therapy for Demoralization in Patients Receiving Hospice Care Phase 2
Active, not recruiting NCT04942756 - GLYPALCARE STUDY - Multicenter, Randomized Study for Evaluating Continuous Glucose Monitoring (CGM) by Using FreeStyle Libre 2 (FSL2) for Preventing Hyperglycemia/Hypoglycemia Crisis in Advanced Oncological Patients. N/A
Completed NCT03260946 - The Use of Alternative Medicine by Palliative Care Patients
Completed NCT04495530 - Information Needs Around Parenteral nUTrition in Cancer
Recruiting NCT05706740 - Towards Cancer Patient Empowerment for Optimal Use of Antithrombotic Therapy at the End of Life
Recruiting NCT06018896 - Vitamin C to Quality of Life in Patients With Terminal Stage Pancreatic Cancer Phase 2
Not yet recruiting NCT06329856 - Exploring Indications and Practices of Administering Artificial Hydration to Terminal Cancer Patients in Taiwan